Health and Healthcare

Is a Generic Diovan for You?

Pills
Thinkstock
Many investors have to worry about the so-called patent cliff in pharmaceutical companies. Generic launches are often priced into most analyst estimates, but these generic launches are always important to look at when they come in the blockbuster drug category with more than $1 billion in annual sales. So what are investors, and patients, supposed to think when Mylan Inc. (NASDAQ: MYL) is launching a generic version of Diovan, a Novartis A.G. (NYSE: NVS) brand product.

Diovan is an important drug because it is indicated for the treatment of hypertension to lower blood pressure. Its annual sales also exceeded $2 billion. This may sound like a first, but Ranbaxy of India received FDA approval in 2014 to market its generic version of Diovan.

Apart from this generic version of Diovan, Mylan has 284 abbreviated new drug applications (ANDAs) pending FDA approval, which represent $109.2 billion in annual brand sales, according to IMS Health. Out of the pending ANDAs, 44 are potential first-to-file opportunities.

Mylan is a global pharmaceutical company that offers a growing portfolio of over 1,300 generic pharmaceuticals and several brand medications. The company also offers a range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. Currently, Mylan markets its products in roughly 140 countries and territories with a workforce of over 25,000 people.

Shares of Mylan were down 1% at $55.76 in the last two hours of trading Monday. The stock has a consensus analyst price target of $59.75 and a 52-week trading range of $41.97 to $59.60.

Shares of Novartis did not seem to react to Mylan’s announcement and are up less than 1% at $92.45 in afternoon trading. Something else to note is that Novartis has a market cap of $223 billion, compared to Mylan’s market cap of $21 billion. Novartis has a consensus analyst price target of $100.87 and a 52-week trading range of $77.90 to $96.97.

ALSO READ: America’s Most (and Least) Healthy States

Sponsored: Attention Savvy Investors: Speak to 3 Financial Experts – FREE

Ever wanted an extra set of eyes on an investment you’re considering? Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help guide you through the financial decisions you’re making. And the best part? The first conversation with them is free.Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.